Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8059189 | 0.92 | CYP1A2 (0.68) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16396868 | 0.91 | AOC3 (0.58) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL31160290 | 0.83 | TSHR (0.58) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20973086 | 0.83 | CYP1A2 (0.58) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1903558 | 0.83 | NPSR1 (0.50) | ALDH1A1LMNAPKMMAPTALOX12 | |
| SCHEMBL13920481 | 0.83 | ALDH1A1 (0.49) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL185065 | 0.83 | CYP1A2 (0.68) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9943885 | 0.83 | CYP1A2 (0.44) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4341722 | 0.83 | CYP1A2 (0.58) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29675845 | 0.83 | NPSR1 (0.50) | ALDH1A1LMNAPKMMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-10829441-B2 | Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke | THE UNIVERSITY OF TOLEDO (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-20190144377-A1 | Reactive Oxygen Species-Sensitive Nitric Oxide Synthase Inhibitors for the Treatment of Ischemic Stroke | THE UNIVERSITY OF TOLEDO (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2018156595-A1 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3002278-A1 | GUANIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-20090253864-A1 | IL-21 Derivatives and Variants | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20060228331-A1 | IL-21 Derivatives and variants | NOVO NORDISK A/S (DK) | 2006-10-12 | — | — | US | disclosed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | disclosed |
| US-6933295-B2 | Substituted isoindoles and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | disclosed |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | TSHR 1439/4885CYP1A2 4863/4885CYP2D6 4404/4885 |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | F2, SERPINC1, F11 | TSHR 2719/4885CYP1A2 119/4885CYP2D6 1155/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | TSHR 1439/4885CYP1A2 4863/4885CYP2D6 4404/4885 |
| US-20190144377-A1 | Reactive Oxygen Species-Sensitive Nitric Oxide Synthase Inhibitors for the Treatment of Ischemic Stroke | NOS3, NOS1, NOS2 | TSHR 1949/4885CYP1A2 1218/4885CYP2D6 2846/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | TSHR 922/4885CYP1A2 3849/4885CYP2D6 3016/4885 |
| US-20090253166-A1 | Conjugation of Peptides | DNPEP, ENPEP, ANPEP | TSHR 922/4885CYP1A2 3849/4885CYP2D6 3016/4885 |
| US-10829441-B2 | Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke | NOS3, NOS1, NOS2 | TSHR 1949/4885CYP1A2 1218/4885CYP2D6 2846/4885 |
| US-20060228331-A1 | IL-21 Derivatives and variants | IL2, IL15, IL23R | TSHR 2480/4885CYP1A2 584/4885CYP2D6 1426/4885 |
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | TSHR 4480/4885CYP1A2 4504/4885CYP2D6 4787/4885 |
| US-20090253864-A1 | IL-21 Derivatives and Variants | IL2, IL15, IL23R | TSHR 2480/4885CYP1A2 584/4885CYP2D6 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.